NCT00006361已完成2 期
A Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
RATIONALE: SU5416 may stop the growth of cancer cells by stopping blood flow to the tumor.
PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and neck.
详细描述
OBJECTIVES:
- Determine the effect of SU5416 on survival and tumor response in patients with advanced or recurrent squamous cell carcinoma of the head and neck.
- Determine the safety and toxicity of SU5416 in these patients.
OUTLINE: Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed for 1 year.
PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within 1.4 years.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
SU5416 in Treating Patients With Advanced Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00005642Case Comprehensive Cancer Center19
已完成
1 期
SU5416 and Paclitaxel in Treating Patients With Advanced CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT00006257City of Hope Medical Center
终止
2 期
SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously TreatedRecurrent MelanomaStage IV MelanomaNCT00006003National Cancer Institute (NCI)35
已完成
2 期
SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone TherapyProstate CancerNCT00006002University of Chicago36
已完成
2 期
SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney CancerKidney CancerNCT00006384City of Hope Medical Center